PCOS Hormones: How GLP-1s Affect Your Cycle

Key Takeaways

GLP-1 receptor agonists have been shown in multiple studies to reduce testosterone and LH levels—two PCOS hormones closely tied to cycle irregularity—alongside driving weight loss.
A 2025 network meta-analysis published in Frontiers in Endocrinology found GLP-1 receptor agonists outperformed metformin and inositol on several hormonal and metabolic markers in women with PCOS.
A randomized controlled trial of tirzepatide plus metformin in overweight Chinese women with PCOS reported improvements in menstrual regularity and androgen levels after just 12 weeks.
GLP-1 receptors are present in ovarian tissue, which may explain why these drugs affect reproductive function beyond the indirect effects of weight loss alone.
None of these medications are currently approved specifically for PCOS or cycle regulation—always consult a qualified healthcare provider before starting or changing any treatment.

What do GLP-1 medications actually do to PCOS hormones?

GLP-1 medications change several PCOS-related hormones at once — lowering insulin, reducing androgens (male-type hormones like testosterone), and nudging the menstrual cycle toward a more regular pattern. The changes aren’t cosmetic; they trace back to specific biological pathways that connect blood sugar control to ovarian function.

PCOS often starts with insulin resistance — the body’s cells stop responding well to insulin, so the pancreas pumps out more of it. That excess insulin tells the ovaries to make more androgens, which then disrupts ovulation. GLP-1 medications slow stomach emptying and signal the pancreas to release insulin only when blood sugar is actually rising, which keeps insulin levels lower overall. A 2025 systematic review and meta-analysis found that GLP-1 receptor agonists significantly reduced fasting insulin in women with PCOS compared to control groups across randomized controlled trials.

Lower insulin means less androgen stimulation. A 2025 literature review on incretin therapy and ovarian function (source) found that GLP-1 medications reduced total testosterone and free androgen index (a measure of how much active testosterone is circulating) in women with PCOS. Less circulating testosterone can ease symptoms like excess hair growth and acne, though the degree of improvement varies from person to person.

The menstrual cycle picture is more complicated, but still meaningful. A network meta-analysis published in 2025 found GLP-1 receptor agonists improved menstrual regularity in women with PCOS, with effects comparable to metformin. Some of that improvement likely comes from weight loss itself — even a 5–10% reduction in body weight can shift hormone levels enough to restore more regular ovulation — but GLP-1 medications also appear to act on the hypothalamus (the brain region that controls the hormonal signals sent to the ovaries), separate from weight loss alone. A 2025 review on the reproductive-metabolic framework in the GLP-1 era (source) describes direct GLP-1 receptor activity in the hypothalamus and ovaries as a likely contributor to these hormonal shifts.

Specific numbers worth knowing:

The 2025 systematic review found GLP-1 receptor agonists reduced LH/FSH ratio (a hormonal imbalance marker common in PCOS) compared to controls.
A 2025 randomized controlled trial of tirzepatide combined with metformin (source) in Chinese women with PCOS showed reductions in testosterone and improvements in menstrual frequency over a short treatment period.
The evidence map published in 2025 notes that SHBG (sex hormone-binding globulin, a protein that binds testosterone and makes it less active) tends to rise with GLP-1 treatment — meaning even if total testosterone doesn’t drop dramatically, less of it is free to cause symptoms.

GLP-1 medications don’t fix PCOS. They shift the hormonal environment in ways that may reduce symptoms and improve cycle regularity, but individual responses differ, and the research is still building.

This content is for general informational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Talk to a qualified healthcare provider before starting, stopping, or changing any medication or treatment plan.

Which hormonal markers have clinical studies measured—and what changed?

Clinical studies measuring PCOS hormones have tracked several markers before and after GLP-1 medication use, and the results show meaningful shifts in the hormonal patterns that drive the condition.

Researchers measure androgens (male-type hormones like testosterone that are elevated in many people with PCOS), insulin-related markers, and cycle regulators like LH and FSH (luteinizing hormone and follicle-stimulating hormone, which control ovulation). Here’s what the evidence shows across those categories.

Androgens

Testosterone and free androgen index (FAI)—which reflects how much active testosterone is circulating—both dropped in multiple trials of GLP-1 medications. A systematic review and meta-analysis of randomized controlled trials found that GLP-1 receptor agonists significantly reduced total testosterone and FAI compared to control groups. A separate network meta-analysis confirmed GLP-1 medications outperformed several comparators on androgen reduction. Lower androgens often mean less excess hair growth and less acne, though individual responses vary.

Insulin and insulin resistance

HOMA-IR is a calculated score that estimates how resistant your cells are to insulin—the higher the number, the harder your body is working to manage blood sugar. GLP-1 medications consistently reduced HOMA-IR in PCOS trials, according to a scientific literature review covering ovarian function outcomes. A prospective randomized trial in Chinese women with PCOS showed improvements in fasting insulin after short-term treatment with tirzepatide combined with metformin.

LH and the LH-to-FSH ratio

An elevated LH-to-FSH ratio is a hallmark of PCOS and disrupts the hormonal signal that triggers ovulation. The evidence map of incretin-based medications in PCOS reported reductions in LH levels across several studies, which may explain why some people see more regular cycles during treatment.

Sex hormone-binding globulin (SHBG)

SHBG is a protein that binds to testosterone and keeps it inactive. Low SHBG means more free testosterone causing symptoms. Several studies cited in the metabolic-hormonal interplay review found that GLP-1 medications raised SHBG levels, effectively reducing the amount of active testosterone in circulation.

The evidence does not yet show clearly whether these hormonal changes persist long-term after stopping medication. Talk with your doctor about what these markers mean for your specific situation before drawing conclusions about your own results.

This content is for general informational purposes only and is not medical advice. It does not replace a conversation with a qualified healthcare provider who knows your full medical history.

Does weight loss alone explain the hormonal shifts, or is something else happening?

Weight loss alone does not fully explain the hormonal shifts seen with GLP-1 medications — the drugs appear to act directly on PCOS hormones through pathways that exist separately from how much weight a person loses. That distinction matters, because it changes what you can realistically expect and why.

A 2025 systematic review and meta-analysis of randomized controlled trials found that GLP-1 receptor agonists reduced testosterone levels and improved menstrual regularity in women with PCOS, even after researchers accounted for weight loss. If the hormone changes were purely a side effect of losing weight, the improvements would track almost perfectly with how many kilograms a person dropped. They did not.

A 2025 literature review on incretin therapy and ovarian function (source) explains one reason why. GLP-1 receptors — the docking sites these medications attach to — exist in the ovaries, the hypothalamus (a small brain region that controls hormone signaling), and the pituitary gland (which sends the hormonal “go” signal to the ovaries). When a GLP-1 medication binds to those receptors, it quiets the overactive signaling that drives excess androgen production. Androgens are the hormones, like testosterone, that are often elevated in PCOS and linked to irregular periods and unwanted hair growth.

A 2025 review on the reproductive-metabolic framework in the GLP-1 era (source) describes this as a dual mechanism: the medications reduce insulin resistance (which itself drives androgen overproduction) and act on the brain-ovary signaling axis at the same time. Neither effect depends entirely on the other.

Two specific findings make this concrete. A randomized controlled trial of tirzepatide plus metformin in Chinese women with PCOS found improvements in LH-to-FSH ratio (a hormone balance marker) and testosterone within 12 weeks — a timeline that outpaced the degree of fat loss observed. A network meta-analysis comparing GLP-1 agonists, metformin, and inositol found that GLP-1 agonists produced greater reductions in testosterone than metformin despite similar weight outcomes in some comparisons, pointing to a mechanism beyond calorie-driven fat loss.

Weight loss is not irrelevant. Losing even 5–10% of body weight does improve hormone levels on its own. GLP-1 medications appear to add something on top of that — a direct conversation with the hormonal system that does not wait for the scale to move.

This content is for general informational purposes only and is not medical advice. It does not replace a conversation with your doctor, endocrinologist, or other qualified healthcare provider. Individual results vary. Always consult a licensed healthcare professional before starting, changing, or stopping any medication.

How do GLP-1s compare to metformin and inositol for hormonal outcomes in PCOS?

GLP-1 medications, metformin, and inositol each improve PCOS hormones through different pathways, and a recent network meta-analysis found that GLP-1 receptor agonists (GLP-1 RAs) produced the largest reductions in testosterone and fasting insulin among the three options for women with polycystic ovary syndrome. No single treatment wins on every measure, and the right choice depends on your individual metabolic picture.

What the comparison data actually shows

A 2025 network meta-analysis compared GLP-1 RAs, metformin, and inositol head-to-head across multiple hormonal and metabolic markers in women with PCOS. The network meta-analysis found:

GLP-1 RAs produced the greatest reductions in total testosterone and fasting insulin compared to both metformin and inositol.
Metformin outperformed inositol on several metabolic markers, including fasting glucose and HOMA-IR (a measure of how resistant your cells are to insulin).
Inositol showed modest improvements across hormonal markers but ranked lowest among the three for most outcomes measured.
All three treatments reduced androgen levels (male-type hormones like testosterone that are often elevated in PCOS) to some degree.

How GLP-1s work differently

Metformin lowers insulin primarily by reducing the amount of glucose your liver releases into the blood. Inositol acts as a messenger molecule that helps insulin do its job inside cells. GLP-1 RAs do both of those things indirectly, and they also slow digestion, reduce appetite, and directly affect the brain’s hunger signals. Because high insulin drives the ovaries to produce excess testosterone in PCOS, lowering insulin through any of these routes tends to bring testosterone down with it—but GLP-1 RAs appear to pull harder on that lever. A systematic review and meta-analysis of randomized controlled trials found that GLP-1 RAs reduced testosterone more substantially than metformin or inositol alone.

Combining treatments

Some clinicians pair GLP-1 RAs with metformin rather than choosing one or the other. A randomized controlled trial in Chinese women with PCOS found that short-term tirzepatide (a dual GLP-1/GIP receptor agonist) combined with metformin improved testosterone, menstrual regularity, and metabolic markers more than either drug alone, per the tirzepatide + metformin RCT. Combination use carries its own considerations around side effects and cost, so that conversation belongs with your prescribing clinician.

The practical takeaway

GLP-1 RAs show the strongest hormonal signal in the current evidence, but metformin has decades of safety data and is far cheaper. Inositol is available without a prescription and has a low side-effect profile. Your metabolic lab values, weight, insurance coverage, and reproductive goals all shape which option—or combination—makes sense for you.

This content is for general informational purposes only and is not medical advice. Talk to a qualified healthcare provider before starting, stopping, or changing any medication or supplement.

What does real-world prescribing data show about incretin use in women with PCOS?

Real-world prescribing data on incretin use in women with PCOS shows a sharp rise in prescriptions since 2021, with most patients receiving these medications specifically because of metabolic problems tied to their condition. A 2025 cohort study from a Polish private healthcare network tracked exactly this pattern.

The study, published in PMID 42297761, followed women with PCOS prescribed incretin-based therapies—a category that includes GLP-1 receptor agonists like semaglutide and dual-action drugs like tirzepatide. The data revealed:

The majority of women had obesity or overweight at their first prescription, meaning clinicians were reaching for these drugs primarily to address weight and insulin resistance, not fertility alone.
Prescribing accelerated year over year, with newer dual-action agents gaining ground on older GLP-1-only options.
Women in the cohort had multiple metabolic concerns at baseline: elevated blood sugar, high triglycerides, and irregular menstrual cycles.

Observational cohorts have real limits. They can tell you who is getting a drug and when, but they cannot prove the drug caused any particular outcome the way a controlled trial can. The Polish study did not randomize patients or include a comparison group that received no treatment.

What real-world data does capture is the full range of patients who actually show up in clinics, not just the carefully selected volunteers in a trial. The women in this cohort were older on average and had more complex health profiles than participants in many published trials—a difference that matters if you’re trying to judge whether trial results will translate to everyday practice.

A 2025 evidence map published in PMID 42106472 reviewed the broader landscape of incretin research in PCOS and found that real-world studies remain sparse compared to controlled trials. Most of the evidence base still comes from randomized trials, which tend to be short (12 to 24 weeks) and small (often fewer than 100 participants). That gap between trial conditions and real clinical life is exactly why the Polish cohort data matters: prescribing is outpacing the evidence, and clinicians are making decisions with incomplete long-term data.

If you have PCOS and are considering a GLP-1 medication, ask your doctor how the real-world profile of patients in studies like this one compares to your own health history.

This content is for general informational purposes only and is not medical advice. It does not replace a conversation with a qualified healthcare provider who knows your individual health history.

What should women with PCOS ask their doctor before trying a GLP-1 medication?

Women with PCOS considering a GLP-1 medication should ask their doctor several specific questions before starting — about how the drug may affect their hormones, fertility, and any medications they already take. The answers matter more for PCOS than for weight loss alone, because GLP-1 drugs appear to change reproductive hormone levels, not just body weight.

Start with the hormone picture

Ask your doctor to explain how a GLP-1 might affect your specific hormone levels. A 2025 meta-analysis of randomized controlled trials found that GLP-1 receptor agonists lowered testosterone and fasting insulin in women with PCOS and improved menstrual regularity in some participants. Your hormone panel may shift. Your doctor should plan to recheck it.

Questions to bring to your appointment

“Should we test my AMH, LH, FSH, and testosterone before I start, so we have a baseline?” A 2025 review found that GLP-1 drugs can change ovarian function markers. A pre-treatment snapshot lets you track real change versus normal fluctuation.
“Could this medication make me more fertile than I expect?” Improved ovulation is a documented effect in some women with PCOS, according to a 2025 evidence map. If pregnancy is not your goal right now, ask your doctor whether your current contraception still fits your needs.
“How does this compare to metformin or inositol for my situation?” A 2025 network meta-analysis compared GLP-1 drugs, metformin, and inositol head-to-head in women with PCOS and found differences in how each one affects weight, insulin, and androgen levels. Your doctor can match the option to your lab results and goals.
“If I’m already taking metformin, is combining it with a GLP-1 safe and useful?” A 2025 randomized controlled trial tested tirzepatide plus metformin in women with PCOS and found the combination improved metabolic and hormonal outcomes more than either drug alone. Ask whether that applies to your case.
“How often will we check my labs once I start?” A 2025 real-world cohort study found that women with PCOS using incretin-based therapies had varied clinical profiles. Monitoring should fit your individual situation, not follow a fixed schedule.
“What side effects should I watch for that are specific to PCOS, not just general GLP-1 side effects?” A 2025 review on anti-obesity drugs in reproductive dysfunction notes that the hormonal effects of these medications in PCOS are still being studied. Your doctor should be honest about what is known and what remains unclear.

Bring your current medication list, your most recent labs, and your family planning intentions. Those three things shape the conversation more than anything else.

This content is for general informational purposes only and is not medical advice. It does not replace a conversation with your own doctor, who knows your full health history.

FAQ

Can GLP-1 medications help regulate my menstrual cycle if I have PCOS?

Some clinical studies have reported improvements in menstrual regularity in women with PCOS taking GLP-1 receptor agonists, including a 12-week randomized trial of tirzepatide plus metformin published in Diabetes, Obesity & Metabolism (PMID 42236268). These findings are promising but come from relatively short trials with specific patient groups, so they cannot be generalized to every woman with PCOS.

How do GLP-1 drugs affect PCOS hormones like testosterone and LH?

Multiple studies have measured reductions in free testosterone, total testosterone, and the LH-to-FSH ratio—all key PCOS hormones—in women treated with GLP-1 receptor agonists. A 2025 systematic review and meta-analysis in Cureus (PMID 42116999) found statistically significant reductions in testosterone alongside improvements in insulin resistance.

Do GLP-1 receptors exist in the ovaries, or do these drugs only work through weight loss?

GLP-1 receptors have been identified in ovarian tissue, the endometrium, and the hypothalamic-pituitary axis, according to a review in the International Journal of Molecular Sciences (PMID 42278283). This suggests these drugs may directly influence reproductive function, not only through the indirect effects of losing body weight.

Are GLP-1 medications approved to treat PCOS or hormonal imbalances?

No GLP-1 receptor agonist is currently approved by the FDA specifically for PCOS or menstrual cycle regulation. Their approved indications are type 2 diabetes management and, for some agents, chronic weight management in adults meeting specific BMI criteria.

How do GLP-1s compare to metformin for improving PCOS hormones?

A 2025 network meta-analysis in Frontiers in Endocrinology (PMID 42490840) found GLP-1 receptor agonists ranked higher than metformin and inositol on several hormonal and metabolic outcomes, including testosterone reduction and improvements in the LH-to-FSH ratio. Metformin still has a much longer safety record in women with PCOS, so the comparison is not straightforward.

What does real-world data show about women with PCOS using incretin-based therapies?

A cohort study from a Polish private healthcare network (PMID 42297761) found that incretin-based therapy use in women with PCOS grew substantially between 2019 and 2023, with most users being overweight or obese and having insulin resistance. The study noted that prescribing patterns shifted toward GLP-1 receptor agonists over time, though off-label use was common.

Is tirzepatide being studied specifically for PCOS hormones?

Yes—a prospective randomized controlled trial published in Diabetes, Obesity & Metabolism (PMID 42236268) tested 12 weeks of tirzepatide combined with metformin in overweight and obese Chinese women with PCOS and found improvements in androgen levels and menstrual regularity compared to metformin alone. Longer trials in more diverse populations are still needed.

Should I stop metformin if I start a GLP-1 medication for PCOS?

That decision depends on your individual health profile and should be made with your prescribing physician. Some of the studies reviewed here, including the tirzepatide trial (PMID 42236268), tested combination therapy rather than replacement, suggesting the two drugs may work together rather than one substituting for the other.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs that require clinical supervision — talk to a licensed healthcare provider before starting, stopping, or changing any treatment.